1 unchanged sentence
10b5-1 Trading Plans
−Removed: the fiscal quarter ended September 30, 2025, no director or “officer” (as defined in Rule 16a-1(f) under the Exchange Act)
−Removed: of the Company adopted or terminated any “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,”
+Added: the fiscal quarter ended March 31, 2026, no director or “officer” (as defined in Rule 16a-1(f) under the Exchange Act) of
+Added: the Company adopted or terminated any “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,”
as each term is defined in Item 408(c) of Regulation S-K.
−Removed: License Agreement
−Removed: On November 10, 2025, we received the Notice
−Removed: from Villani alleging that we breached the License Agreement as a result of our recent strategic shift to focus on over-the-counter
−Removed: pharmaceutical products.
−Removed: The Notice alleges that we (i) failed to use Commercially Reasonable Efforts (as defined in the License
−Removed: Agreement) to pursue a prescription product business, (ii) failed to provide Villani with advance notice of certain submissions to
−Removed: regulatory authorities, (iii) used Licensed Know-How (as defined in the License Agreement) outside of the Field (as defined in the
−Removed: License Agreement), and (iv) our anticipated OTC kits do
−Removed: not qualify as Licensed Products (as defined in the License Agreement).
−Removed: On November 11, 2025, Villani delivered the Additional
−Removed: Notice whereby Villani requested (i) the reversion and assignment of all assets regarding Spongilla -based products back to
−Removed: Villani, (ii) that we preserve all Spongilla inventory, and (iii) we preserve all documents, data, and tangible
−Removed: materials related to Spongilla .
−Removed: We dispute the allegations contained in the Notice and Additional Notice and are
−Removed: engaged in discussions with Villani to resolve such disputes.
−Removed: If the parties are unable to reach a resolution, then the either
−Removed: party, pursuant to the License Agreement, may file for arbitration or termination of the License Agreement.
−Removed: To date, the License
−Removed: Agreement has not been terminated and continues in full force.
−Removed: At this point in time, we are unable to predict the final outcome of
−Removed: this dispute.
−Removed: Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Dermata Therapeutics, Inc., dated July 30, 2025 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the SEC on July 30, 2025).
+Added: Letter to Securities and Exchange Commission from Baker Tilly US, LLP, dated February 3, 2026 (incorporated by reference to Exhibit 16.1 to the Company’s Current Report on Form 8-K filed on February 3, 2026).
Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a).
−Removed: Certification of the Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a).
+Added: Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a).
Certification of Principal Executive Officer and Principal Financial Officer pursuant to Rule 13a-14(b) or Rule 15d-14(b).
8 unchanged sentences
Therapeutics, Inc.
−Removed: November 14, 2025
and Chief Executive Officer
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.